Wall Street has perceived the company to have an almost unbreachable defense against competition with its offerings of ...

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the ...

The S&P 500 and Nasdaq both fell by a whopping 1.46 percent and 3.07 percent, respectively, over fears that China is ...

Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

It wants to crush (forget 'turn back") the clock on diversity and inclusion in America. Fighting bac requires looking back - and getting it right this time.

Johnson & Johnson (JNJ ... despite the company beating Wall Street expectations on revenue by $70 million and reporting results on earnings per share in line with estimates.

With the stock market overbought and insiders selling, shares of these five outstanding large-cap companies look like just ...